Annual vaccinations reduced the number of hospitalisations in children by 50%, not only...
UCB’s trial of bimekizumab in psoriasis patients meets goals
UCB has announced that the Phase III BE VIVID clinical trial of its bimekizumab met all primary and key secondary endpoints in moderate-to-severe chronic plaque psoriasis patients.
IDWeek 2019: Seasonal influenza vaccines prove their worth, but better vaccines are still needed
Annual vaccinations reduced the number of hospitalisations in children by 50%, not only in patients with pre-existing conditions but also in healthy children (40% of the cases).
Janssen seeks expansion into psoriatic arthritis with latest Tremfya FDA filing
Tremfya is already approved across seven major markets for psoriasis and was approved for psoriatic arthritis in Japan in April 2018.
TrialSpark and Pfizer partner to accelerate clinical trials
Pfizer will extend its clinical trials to community doctors who have not previously been involved in any study investigations after the company signed a multi-year collaboration with TrialSpark.
FDA accepts design change of Calliditas Therapeutics’ NefIgArd study
The US Food and Drug Administration (FDA) has accepted a design change of part B of Calliditas Therapeutics’ NefIgArd trial evaluating Nefecon in IgA Nephropathy (IgAN), a chronic autoimmune kidney disorder.
Aimmune begins enrolling egg allergy patients in Phase II study
Aimmune Therapeutics has recruited the first patient in a Phase II clinical trial evaluating investigational biological drug AR201 for the treatment of egg allergy.
Aurinia still has potential Phase III lupus nephritis mortality risk
Lupus nephritis is an inflammation of the kidney caused by systemic lupus erythematosus.
Provention Bio doses first patients in PREVAIL trial of PRV-3279
Provention Bio has dosed the first patients in its Phase Ib/IIa PREVAIL clinical trial of humanised diabody PRV-3279.
Janssen to trial mosaic-based HIV-1 preventive vaccine
Janssen Vaccines & Prevention, a Johnson & Johnson unit, along with a consortium of partners is set to initiate a Phase III clinical trial to evaluate an investigational preventive vaccine for HIV-1 infection.